Blue Earth Diagnostics
Clinical trials sponsored by Blue Earth Diagnostics, explained in plain language.
-
New imaging agent shows promise for spotting prostate cancer
Diagnosis CompletedThis early-phase study tested a new radioactive imaging agent called rhPSMA-7.3 (18F) in 24 people: healthy volunteers and those with prostate cancer. The goal was to check its safety and how well it can highlight prostate cancer cells on scans. Researchers measured side effects …
Phase: PHASE1 • Sponsor: Blue Earth Diagnostics • Aim: Diagnosis
Last updated May 09, 2026 05:35 UTC
-
New imaging agent spots hidden prostate cancer recurrence
Diagnosis CompletedThis study tested a new imaging agent called rhPSMA-7.3 (18F) for PET scans in 391 men with suspected prostate cancer recurrence based on rising PSA levels after initial treatment. The goal was to see how well the scan could detect where the cancer had returned. Results showed th…
Phase: PHASE3 • Sponsor: Blue Earth Diagnostics • Aim: Diagnosis
Last updated May 09, 2026 05:34 UTC
-
Which PET tracer blurs less? study aims to sharpen prostate cancer detection
Diagnosis CompletedThis study involved 55 men whose prostate cancer returned after surgery, with very low PSA levels. Researchers compared two different radioactive tracers (piflufolastat and flotufolastat) used in PET scans to see which one caused less radioactivity in the bladder, potentially mak…
Phase: PHASE4 • Sponsor: Blue Earth Diagnostics • Aim: Diagnosis
Last updated May 06, 2026 16:01 UTC